SPONTAN Expands Patient Access via National Pharmacy Network
Released
Released
Announcement PDF
SPONTAN® Expands Patient Access via National Pharmacy
Networks
20 May 2025
Highlights
•
•
•
•
•
SPONTAN® now available through TerryWhite Chemmart's network of over six hundred
pharmacies nationwide
New barcoded commercial packaging developed to support pharmacy integration and telehealth
pathways
Patients with prescriptions from healthcare professionals can now have them filled at
participating pharmacies across Australia
National pharmacy access milestone achieved for SPONTAN under TGA’s Special Access Scheme
(SAS) and Authorised Prescriber Scheme (APS)
Enables collection of ‘real-time’ patient and prescriber responses to SPONTAN
LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that SPONTAN® is
now available through TerryWhite Chemmart's (“TWC”) national pharmacy network, representing a key step in
the Company’s efforts to expand its patient access infrastructure under its previously announced partnership with
Symbion Pty Ltd.
This achievement represents a pivotal milestone in LTR Pharma's access and readiness strategy, transitioning
SPONTAN from limited availability to broader pharmacy availability under regulated pathways. The
implementation provides LTR Pharma access to over six hundred pharmacy locations throughout Australia.
TerryWhite Chemmart, a subsidiary of EBOS Group alongside Symbion, operates one of the country's largest
pharmacy networks and maintains a strong presence in metropolitan and regional areas.
Commercial Packaging
LTR Pharma has developed new commercial packaging for SPONTAN, designed specifically for pharmacy
distribution. The packaging incorporates TGA-compliant labelling, patient information materials, and pharmacystandard barcodes. These barcodes are designed to enable integration with future telehealth platforms, providing
patients with a direct and streamlined pathway to healthcare professionals for consultation and prescribing.
Prescription Process
Patients with a prescription for SPONTAN from an authorised healthcare professional can now have their
prescriptions filled at any participating TerryWhite Chemmart, Pharmacy Choice, or healthSAVE pharmacies.
Dispensing occurs under the oversight of registered healthcare professionals and operates under the TGA's
Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS).
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Operational Implementation
Following the January 2025 announcement of LTR Pharma's distribution agreement with Symbion, the companies
have completed all key integration milestones, including:
•
Integration of inventory management systems
•
Implementation of TGA-compliant tracking protocols
•
Establishment of product handling procedures
•
Completion of pharmacist education and training materials
As part of ongoing pharmacist engagement, LTR Pharma will be presenting at the TerryWhite Chemmart
Masterclass during the week of 23 June 2025.
This educational session is designed to inform and equip
pharmacists across the TerryWhite network with clinical insights and dispensing guidance for SPONTAN under the
TGA’s Special Access and Authorised Prescriber Schemes.
Real-World Data Collection
The expanded pharmacy rollout enables LTR Pharma to gather valuable real-world data on SPONTAN usage. This
data supports the Company’s regulatory strategy and preparations for a full commercial launch following
regulatory approval in Australia and for the planned US launch of ROXUS in 2026, providing insights into
prescribing patterns, patient experience, and market dynamics.
LTR Pharma Executive Chairman, Lee Rodne, said:
"The national rollout of SPONTAN through TerryWhite Chemmart and other pharmacy networks represents the
implementation of our Symbion partnership and delivers convenient physical access points for patients across the
country. This milestone supports our commitment to improving the availability of SPONTAN across Australia while we
progress our regulatory pathway. Patients can now have their SPONTAN prescriptions filled at participating pharmacies
nationwide, providing a direct pathway from healthcare professional to pharmacy dispensing."
- ENDS -
This announcement has been approved by the Board of Directors.
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
About LTR Pharma
LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative
therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal
drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas.
LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile
dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is
now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal
Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated,
patient-centric treatments that enhance quality of life.
For further information please contact:
Media enquiries
Haley Chartres
haley@hck.digital
Investor enquiries
Peter McLennan
investors@ltrpharma.com
1800 519 711 | ltrpharma.com | info@ltrpharma.com
LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)
Share your feedback
Discover